8-K: Bionomics Shareholders Approve Re-domiciliation to the U.S. via Scheme of Arrangement

Bionomics shareholders have approved the company's re-domiciliation to the United States, with Neuphoria Therapeutics Inc. becoming the ultimate parent company.

Summary

• Bionomics Limited shareholders have voted to approve the Scheme of Arrangement, which will result in the company re-domiciling from Australia to the United States.
• The re-domiciliation will see Neuphoria Therapeutics Inc., a Delaware corporation, become the ultimate parent company of Bionomics.
• 96% of the votes cast by Bionomics shareholders were in favor of the Scheme.
• 87% of Bionomics shareholders present and voting also supported the Scheme.
• The Scheme is still subject to several conditions, including approval from the Supreme Court of New South Wales, and the independent expert not withdrawing their positive conclusion.
• The Supreme Court hearing is scheduled for December 16, 2024.
• If all conditions are met, the implementation of the Scheme is expected to occur on or about December 24, 2024.
• Neuphoria shares are expected to begin trading on Nasdaq under the symbol NEUP on or around December 24, 2024.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the successful shareholder vote and the anticipated completion of the re-domiciliation. The move is a strategic positive for the company.

Positives

• Shareholder approval for the re-domiciliation was secured with a strong majority.
• The re-domiciliation is expected to be completed by December 24, 2024, subject to remaining conditions.
• The company will be listed on the Nasdaq under the new ticker NEUP.

Risks

• The Scheme is still subject to approval by the Supreme Court of New South Wales.
• The independent expert could withdraw or adversely modify their conclusion.
• There are remaining conditions that need to be satisfied or waived before the Scheme can be implemented.

Future Outlook

The company anticipates the re-domiciliation to be completed around December 24, 2024, with Neuphoria shares commencing trading on Nasdaq under the symbol NEUP on or around that date.

Industry Context

This re-domiciliation is a strategic move for Bionomics, potentially providing better access to capital markets and investors in the U.S., which is a common strategy for international biotech companies seeking growth.

Comparison to Industry Standards

• Many international biotech companies have re-domiciled to the US to gain access to larger capital markets and a more biotech-focused investor base.
• Companies like CSL Limited (CSL.AX) and Cochlear Limited (COH.AX), while not re-domiciling, have established significant operations in the US to tap into the market.
• The move to list on Nasdaq is a common strategy for biotech companies seeking higher valuations and access to specialized investors, similar to companies like Imugene (IMU.AX) which has an ADR listing in the US.

Stakeholder Impact

• Shareholders will see their Bionomics shares converted to Neuphoria shares.
• The company will have a new listing on the Nasdaq.
• The re-domiciliation may provide better access to capital and growth opportunities.

Next Steps

• The Supreme Court of New South Wales will review the Scheme on December 16, 2024.
• The company will work to satisfy or waive any remaining conditions.
• Implementation of the Scheme is expected to occur on or about December 24, 2024.
• Neuphoria shares are expected to begin trading on Nasdaq under the symbol NEUP on or around December 24, 2024.

Key Dates

Keywords

re-domiciliation, scheme of arrangement, shareholder approval, Neuphoria Therapeutics, Nasdaq, Bionomics, NEUP, BNOX